I'm with you Drano. Here's a quick discussion I had this

New Post Public Reply Private Reply Replies (2) Message Board
BooDog Drano #15685
I'm with you Drano. Here's a quick discussion I had this morning. Many mentioned here but mainly CTIX and AVXL. Also still seeing sunsplat on the ctix board, relentless misrepresentation trying to implant BS.

Quote:
The manipulation is unreal. 123tom mentioned a few and a group I hang with that primarily shorts stocks (I'll explain more in a bit) reminded me of a couple others, UQM and MDBX. Stocks that get a MAJOR spike and then crash right back down. We've seen some others just this year. I don't short, but it can be done the right way without torturing or being malicious ~ the way it was meant to be. My other group is BP Rising, they simply peg the resistance and cover on the support. Not being greedy like some of the hedge funds or groups like Adam F. Helps me too sometimes, when they start covering and support is confirmed, I can go long again with a bit more confidence. Most of their plays are out of my price range or I hardly seem to have the funds available at the right time.

AVXL wasn't much different as far as the spike went, a lot of hype driving it so many knew the peak wouldn't be sustainable. I like and I use the same strategy gfp927z (what is that ID short for?)...

Quote:

But there is a way to own bio stocks for the longer haul, instead of merely trading them. You can have small positions in a group of favorites and just let them ride for as long as their fundamentals continue to look good. That's how successful private equity outfits like the Baker Bros do it. Another approach is to have a core position and a trading position. For myself I'm content to just follow them out of general interest and for the entertainment value. If I decide to actually invest money again, the strict limit will be $1000 per stock. With this approach you won't get rich, but you'll stay out of trouble.




I have been consistently using both. Light positions in a stock and then loading back up when the chart says to or well ahead of a catalyst and then taking some off around the event or pulling a stop loss if need be. MSTX has been in a sideways range for some time but also has a couple nice catalysts, one soon (by mid December?) and then more on their EPIC study 1q 2016. Took some back off around .43 since the technical weakened but looking to add back on it. ATNM CBAY SYN CTIX CRBP I've been doing the same thing. Took some profits from AVXL and loaded CBAY just in time for it to pull back on me, reminding me not to be so quick to follow the intraday when I'm looking for a longer term swing.
Speaking of intradays, AVXL, 2 days in a row screwed me over, the only thing that saved me from adding back in was the lack of confirmation. Crowin had it right both times on the AVXL thread, I don't follow him and think he may be more of a short but I do try and keep an open mind and not just ignore other ideas. I'm just another rock in the pond so if I see something that might give me an edge I'll take heed and at least be a bit more cautious. I was looking for the 200 dma to hold up better but the low float adds to this volatility. The intraday was showing signs of forming a falling wedge reversal from the daily. My idea was to combine the daily and throw in the intraday, I also mentioned in my post that we'd need to see confirmation. My wedge fell apart shortly after I posted. Is it just shorts? It could be, I didn't see any insider selling. Though I am missing a little over 300K shares post split from the form 5 annual statement and my calculations of the form 4's pre split. Too many posts to go through to see if anyone else addressed that or even caught it. When buyers are staying away or longs are just sitting tight, whatever action there is causing so much volatility but the overall trend is manipulated down because (IMO) hedge funds are whacking out the bid. I think there is institutional interest and whoever it is doing what they can to get whatever they can as low as they can. We'll find out in Jan early Feb when the new numbers come out. Like CTIX, we should see the interest continue so money will be watching. Just need to see if Anavex has something up their sleeve to spark things in the right direction. I'm putting AVXL on early pincher radar soon but it needs to set up a bit more. Divergence still looks a bit weak. Starting to head into the oversolds.
I do like your strategy Gfp927z, have some AVXL in the $4's and looking to load up.
News on ATNM as well so may be able to play that into adding on AVXL. BTW, AVXL on S Ttwits now has over 2013 followers.




Quote:

gfp927z Wednesday, 11/18/15 09:58:04 AM
Re: BooDog post# 1048
Post # of 1049


BooDog, With AVXL they're using the usual shorting techniques like forcing down the bid, but other than the brief Feuerstein article there wasn't a huge accompanying hit piece of the type that happened with CTIX, where they not only trash in great detail the science, but also the CEO and other management's dubious history. The CTIX hit job took months to plan and was a major production, in contrast to AVXL which looks like a one time 'short and move on' opportunity for the short crowd.

AVXL just got way ahead of itself on the upside, having a $500 mil market cap based on a tiny open label Phase 2a. The CEO Missling is a straight arrow compared to Erlich of CTIX, so there wasn't the required ammo for a full fledged long term assault on the stock, in contrast to CTIX. So I'm figuring the AVXL shorts will cover and move on to their next prey and leave the stock alone to gradually recover.

The clinical evidence of efficacy is very early, but AVXL is a potential lotto stock due to the extreme lack of effective Alzheimer's treatments - there are none. The ACHase inhibitors like Aricept, and the NMDA inhibitor Namenda, are basically worthless, but have racked up many billions in sales only because there is no other treatment available. As long as that's the case, interest in AVXL will return. According to Dr. Tracy of NeuroPerspective, AVXL's approach (Sigma-1 receptor) is getting renewed interest in the pharma world. So AVXL has potential as a high risk longer term lotto stock, with a solid CEO in Missling and a $50 mil financing arrangement in place.


Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hamamatsu & AIxMed to Automate Cytology Workflows

Updated Category News Views 2

Why This Collaboration Matters Here comes an interesting tidbit from the world of cytology: Hamamatsu and AIxMed are banding together to tackle workflow inefficiencies. Picture this—two powerhouses coming together to create a tool that might just relieve lab technicians from the tedious task of manually checking cytology slides. In a world where efficiency is king, this...

Continue Reading
Bucket List Wine Dinners Beckon to Los Angeles

Updated Category News Views 1

Sipping on the Extraordinary: LA Wine Soiree When was the last time you had a glass of wine that truly feels like you've unlocked a treasure chest? That's what LearnAboutWine.com is going for with their bucket list wine dinners in Los Angeles. Imagine tasting some of the world's most coveted bottles, all served with a level of polish that screams high-end dining. Led by...

Continue Reading
CAPR Faces Lawsuit and FDA Delay: Investor Alert

Updated Category News Views 0

Trouble Brewin' for Capricor Investors Buckle up, folks. Capricor Therapeutics (NASDAQ: CAPR) is caught in a storm, facing not just the lengthy arm of law with a securities class action, but also a seemingly endless wait with the FDA's decision on their lead product. We're talking serious implications for anyone with skin in the game. The FDA's Delayed Blessing So the...

Continue Reading
Connected Retail Security: Rising Risks and Fragmented Roles

Updated Category News Views 0

Cyber Threats in the Connected Retail Landscape The retail world isn't what it used to be. Walk into a store today, and you're greeted not just by products but a web of interconnected systems screaming for attention. Sure, you've got your old-school POS systems humming along, but they're just one brittle cog in a rattling machine of IoT devices, cloud platforms, and...

Continue Reading
Truist Revolutionizes Banking with 2 Billion Insights

Updated Category News Views 1

A New Frontier in Banking Truist is out here flipping the script in digital banking, pushing a staggering 2 billion AI-driven insights since 2023. Imagine that—two billion insights 'till now, providing the kind of financial street smarts that help folks feel less like they're lost at sea and more like they're the captain of their own financial ship, all thanks to Truist...

Continue Reading
California American Water’s $8.6M Project: Big Move Upfront

Updated Category News Views 1

California's Lincoln Oaks neighborhood is gearing up for some necessary upheaval, thanks to California American Water’s new $8.6 million infrastructure overhaul. For decades, those folks in Sylvan Park have been juggling with the roulette of aging water mains in their backyards. Now, imagine that: backyard pipes begging to turn traitors. It's about time someone decided...

Continue Reading
Yardi Virtuoso AI to Shine at CAIC 2026 Toronto

Updated Category News Views 1

The Scene in Toronto: Yardi's Big AI Showcase There's no denying it—Artificial Intelligence has muscled its way into practically every corner of the business world, and now it's making waves in real estate. Yardi, a familiar name in real estate tech circles, is gearing up to flaunt its Yardi Virtuoso Enterprise at the Canadian Apartment Investment Conference (CAIC) in...

Continue Reading
Mitrade EU Enhances Investor Safety with New Insurance

Updated Category News Views 4

Mitrade's New Insurance: A Safety Net? Mitrade EU is amping up its game with some fresh insurance perks that catch the eye. They're slapping on some extra insolvency protection for clients trading under their CySEC license. Now that sounds like a financial shield anyone would want. Basically, they're adding another layer to the basic regulatory protections, and without...

Continue Reading
McCann Systems Scores Big with Dual AV Awards Wins

Updated Category News Views 0

Piling Up the Accolades: McCann Systems Does It Again You know, getting industry awards can sometimes feel like counting beans, but when a company's snagging them year after year, that’s worth noting. McCann Systems is strutting its stuff with two Commercial Integrator Awards in 2026, cementing their reputation not just here in New Jersey, but across the AV industry....

Continue Reading
Huawei Unleashes Bold New Flagship Devices in Munich

Updated Category News Views 2

Huawei's Bold Move in Munich When I hear about yet another product launch, I often roll my eyes but this one, folks, deserves a second glance. Huawei dropped a news bomb in Munich with their 'Chase the Wild' event, unveiling a huge lineup of flagship gadgets. This isn't your run-of-the-mill release; the mix of smart wearables, tablets, smartphones, and audio gear marks...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding Exempt Principal Trader Dealings in FD Technologies

Updated Category News Views 223

Key Insights on Public Offering Rule 8.5 In the dynamic landscape of finance, transparency is critical, especially regarding trading activities involving exempt principal traders. FD Technologies plc, in compliance with Rule 8.5 of the Takeover Code, has made a significant public disclosure. This regulation emphasizes the necessity for principal traders to maintain an...

Continue Reading
ZenaTech's ZenaDrone Aims for FAA Certification in Agriculture

Updated Category News Views 161

ZenaTech's Ambitious Step Towards FAA Certification In an exciting development for the agricultural technology sector, ZenaTech, Inc. (Nasdaq: ZENA) has taken significant strides with its innovative ZenaDrone 1000. The company has recently applied for the Federal Aviation Authority (FAA) Part 137 certification to utilize its drone in crop spraying applications. This...

Continue Reading
Innovative Lithium Safety Solutions: FCL-X™ Live Showcase

Updated Category News Views 135

Full Circle Lithium and the FCL-X™ Introduction Full Circle Lithium Corp. (TSXV: FCLI, OTCQB: FCLIF) is preparing to present its groundbreaking lithium battery extinguishing solution, the FCL-X™, at the LithiumSAFE Battery Safety Workshop Conference. This much-anticipated event will highlight FCL's commitment to enhancing safety measures in the lithium battery...

Continue Reading
BrainStorm Cell Therapeutics Reports Q3 Financials and Updates

Updated Category News Views 108

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a prominent developer of adult stem cell therapeutics for neurodegenerative disorders, has disclosed its financial outcomes for the third quarter. The company continues to advance its innovative NurOwn program aimed at providing therapeutic...

Continue Reading
Sweet Paris Crêperie Expands with New Franchises in the Midwest

Updated Category News Views 202

Sweet Paris Crêperie Expands into the Midwest Sweet Paris Crêperie & Café, a beloved restaurant brand known for its mouthwatering crêpes and inviting atmosphere, is set to broaden its horizons with exciting plans for expansion into two new states. This ambitious move will see the opening of four new locations in Arkansas and Missouri, enhancing the restaurant's...

Continue Reading